Rheumatic Diseases
We recommend
Bimekizumab in the Treatment of Psoriatic Arthritis
Arthritis can appear in up to a third of patients with psoriasis, mostly after the onset of skin symptoms. Early recognition of this transition by dermatologists and general practitioners is crucial, as early intervention can prevent irreversible joint damage. In the context of effective biological therapy, there is even talk of the potential prevention of arthritis development in individuals with psoriasis.
With Dr. Miroslav Nečas, Ph.D., on the conclusions of the recent consensus of the expert panel on the practice of biological treatment of psoriasis
This February, an expert consensus on the use of bimekizumab in the treatment of psoriasis and…
Dual Inhibition of IL-17A/IL-17F Across the Spectrum of Axial Spondyloarthritis
Many patients with axial spondyloarthritis (axSpA) still have a need to seek additional therapeutic…
No content is currently available on this topic.
Most read on this topic
Interesting links
- Dual Inhibition of IL-17A/IL-17F Across the Spectrum of Axial Spondyloarthritis
- Bimekizumab in the Treatment of Psoriatic Arthritis
- With Dr. Miroslav Nečas, Ph.D., on the conclusions of the recent consensus of the expert panel on the practice of biological treatment of psoriasis
Interesting links